Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
While it is generally understood that Alzheimer's disease (AD) and related dementias (ADRD) is one of the costliest diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease, its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions to mitigate this looming public health crisis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Global economic costs of ADRD are projected to double from $1 trillion to $2 trillion (USD) in the next decade alone (e.g., from 2018 to 2030) [114,115].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 1×
“Moreover, despite improvements in the quality of care for patients and the identification of several potentially modifiable risk factors [118], the causal mechanisms of ADRD are complex, multifactorial and not fully elucidated, and no disease-modifying intervention is available to delay, halt, or reverse the underlyin…”
BackgroundSelf-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70136-x · Cited by 2,466
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412 · cited 1×
“dency among older adults worldwide [1], having a significant impact not only on individuals but also on their families, communities, and societies.”
Background(2015) · HAL · Cited by 2,238
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 5×
“, English Longitudinal Study on Aging, Swedish National Study on Aging) and may supply some of these data, these studies have generally been focused on patients with a dementia diagnosis and rely on a limited range of assessments [4, 28].”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- World Health Organization. First WHO Ministerial Conference on Global Action Against Dementia.
Cited by
Applications of focused ultrasound in the brain: from thermoablation to drug delivery
Meng, Y., Hynynen, K., & Lipsman, N. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00418-z · Cited by 505
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Nandi, A., Counts, N., Chen, S., Seligman, B., Tortorice, D., Vigo, D., & Bloom, D. E. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101580 · Cited by 402
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Self-citationNeuroprotective Herbs for the Management of Alzheimer’s Disease
Gregory, J., Vengalasetti, Y. V., Bredesen, D. E., & Rao, R. V. (2021) · Biomolecules · doi:10.3390/biom11040543 · Cited by 236
“While many new approaches to symptomatic treatment and disease-modifying therapy are currently under development for AD, the final outcome of their development to the market is uncertain [1,2,182,183].”
BackgroundInfluentialWeuve, J., Bennett, E. E., Ranker, L., Gianattasio, K. Z., Pedde, M., Adar, S. D., Yanosky, J. D., & Power, M. C. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8716 · Cited by 209
“Dementia erodes the a ff ected person ’ s independence, imposes emotional and fi nancial burdens on care partners, and levies enormous costs to social safety nets (Alzheimer ’ s Association 2018; El-Hayek et al. 2019).”
InfluentialPromoting Successful Cognitive Aging: A Ten-Year Update
Krivanek, T. J., Gale, S. A., McFeeley, B. M., Nicastri, C. M., & Daffner, K. R. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201462 · Cited by 172
The Humanistic and Economic Burden of Alzheimer's Disease
Monfared, A. T., Byrnes, M. J., White, L. A., & Zhang, Q.-W. (2022) · Neurological Therapeutics · doi:10.1007/s40120-022-00335-x · Cited by 131
“The considerable total societal economic burden of AD includes direct costs (including both medical and non-medical costs) and indirect costs (largely informal care costs, but also lost productivity costs and intangible costs) [7, 60, 61].”
BackgroundManwell, L. A., Tadros, M., Ciccarelli, T. M., & Eikelboom, R. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2101028 · Cited by 122
van de Mortel, L. A., Initiative, A. D. N., Thomas, R. M., & van Wingen, G. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210173 · Cited by 125
Iliyasu, M., Musa, S., Oladele, S., & Iliya, A. I. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1081938 · Cited by 91
Marešová, P., Hruška, J., Klímová, B., Baraković, S., & Krejcar, O. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s264688 · Cited by 104
Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
Habashi, M., Vutla, S., Tripathi, K. K., Senapati, S., Chauhan, P. S., Haviv‐Chesner, A., Richman, M., Mohand, S.-A., Dumulon‐Perreault, V., Mulamreddy, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210766119 · Cited by 88
Robinson, R. L., Rentz, D. M., Andrews, J. S., Zagar, A. J., Kim, Y., Bruemmer, V., Schwartz, R. L., Ye, W., & Fillit, H. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191212 · Cited by 83
“recently reported that there are many hidden societal costs associated with AD, such as underemployment and loss of savings and earnings in the years leading up to the diagnosis, reduced health and well-being of the caregiver, as well as reduced quality of life [48].”
BackgroundZoungas, S., Curtis, A. J., Spark, S., Wolfe, R. S., McNeil, J. J., Beilin, L. J., Chong, T. T. ‐., CLOUD, G. C., Hopper, I., Kost, A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069915 · Cited by 84
Atri, A., Dickerson, B. C., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14333 · Cited by 109
“To achieve the goals of this three-step diagnostic formulation, the DETeCD-ADRD CPG recommends a structured and multi-tiered approachtoassessmentandtestingthatbeginswithafundamentalset ofTier1assessmentsandtests,supplementedasneededbyothertests tailoredtothepatient(seeFigures2–3).”
Self-citationMattke, S., Batie, D., Chodosh, J., Felten, K. M., Flaherty, E., Fowler, N. R., Kobylarz, F. A., O’Brien, K., Paulsen, R., Pohnert, A. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13051 · Cited by 82
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Self-citationCurrent and evolving treatment strategies for the Alzheimer disease continuum
Marasco, R. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 80
Raphael, D. D. L. (2022) · Medicina · doi:10.3390/medicina58070906 · Cited by 63
Drug Delivery to the Brain: Recent Advances and Unmet Challenges
Bhunia, S., Kolishetti, N., Vashist, A., Yndart, A., Brooks, D., & Nair, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122658 · Cited by 77
“As per the estimation of WHO in 2016, one-third of the global population is impacted by neurological or psychiatric conditions at some point in their lifetime with Alzheimer’s disease (AD) alone is estimated to cost US$2 trillion by 2030 [2].”
MethodSato, H., Tsukamoto‐Yasui, M., Takado, Y., Kawasaki, N., Matsunaga, K., Ueno, S., Kanda, M., Nishimura, M., Karakawa, S., Isokawa, M., et al. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00023 · Cited by 65
“Alzheimer’s disease (AD) is a neurodegenerative condition that is highly prevalent in old age (1) and has a significant socioeconomic impact, which will lead to an increased economic burden in healthcare systems worldwide (2).”
BackgroundNutrition, gut microbiota, and alzheimer’s disease
Romanenko, M., Kholin, V., Koliada, A., & Vaiserman, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.712673 · Cited by 56
“Dementia, particularly Alzheimer’s disease (AD), as the major cause of disability and dependence in elderly persons lead to a significant negative socioeconomic impact (2).”
BackgroundPredicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
Herring, W. L., Gould, I. G., Fillit, H. M., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00273-0 · Cited by 58
Walker, A. C., Bhargava, R., Vaziriyan-Sani, A. S., Pourciau, C., Donahue, E. T., Dove, A. S., Gebhardt, M. J., Ellward, G. L., Romeo, T., & Czyż, D. M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009510 · Cited by 62
“Despite the high prevalence and enormous financial and social burdens imposed on afflicted individuals and their families [2], no effective treatment or cure has been found; moreover, the etiology of these diseases remains largely unknown [3].”
BackgroundGarcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
“Accompanied by the increase in life expectancy, Alzheimer’s disease (AD) has become a major global public health problem with an increasing burden and massive socioeconomic and political impacts [1].”
BackgroundDickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 70
Self-citationhoucke, J. V., Mariën, V., Zandecki, C., Vanhunsel, S., Moons, L., Ayana, R., Seuntjens, E., & Arckens, L. (2021) · Aging Cell · doi:10.1111/acel.13464 · Cited by 52
Sarathlal, K. C., Kakoty, V., Krishna, K. V., Dubey, S. K., Chitkara, D., & Taliyan, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00022 · Cited by 49
Angeles, R. C., Berge, L. I., Gedde, M. H., Kjerstad, E., Vislapuu, M., Puaschitz, N. G., & Husebo, B. S. (2021) · Health Economics Review · doi:10.1186/s13561-021-00333-z · Cited by 58
“Since 2010, the total costs have grown by 35% [4].”
BackgroundGreenfield, E. A., Moorman, S. M., & Rieger, A. (2020) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaa062 · Cited by 53
“The importance of research in this area is predicated on the value of preventing the onset and progression of Alzheimer’s disease and related dementias (ADRD) for individuals, families, and society (El-Hayek et al., 2019).”
BackgroundProtective effect of irisin against Alzheimer’s disease
Chen, K., Wang, K., & Wang, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.967683 · Cited by 50
“Alzheimer’s disease, as a neurodegenerative disease, impacts not only patients and their families but also social security (1, 2).”
BackgroundGoriely, A., Kuhl, E., & Bick, C. (2020) · Physical Review Letters · doi:10.1103/physrevlett.125.128102 · Cited by 41
Ikeuchi, T., Kanda, M., Kitamura, H., Morikawa, F., Toru, S., Nishimura, C., Kasuga, K., Tokutake, T., Takahashi, T., Kuroha, Y., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1040476 · Cited by 39
Building clinically relevant outcomes across the Alzheimer's disease spectrum
Rentz, D. M., Wessels, A. M., Annapragada, A. V., Berger, A., Edgar, C. J., Gold, M., Miller, D. S., Randolph, C., Ryan, J. M., Wunderlich, G., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12181 · Cited by 38
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 37
Ang, L. C., Yap, P. L. K., Tay, S. Y., Koay, W. I., & Liew, T. M. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.12.028 · Cited by 43
Gebril, H. M., Aryasomayajula, A., de Lima, M. R. N., Uhrich, K. E., & Moghe, P. V. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00393-7 · Cited by 40
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
The Excess Costs of Dementia: A Systematic Review and Meta-Analysis
Sontheimer, N., Konnopka, A., & König, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210174 · Cited by 34
“New research suggests that the current state of literature only represents the “tip of the iceberg” of the real-world costs of dementia [56].”
Jang, H., Soroski, T., Rizzo, M., Barral, O., Harisinghani, A., Newton‐Mason, S. M., Granby, S., Vasco, T. D. C., Lewis, C., Tutt, P., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.716670 · Cited by 52
Bilousova, T. V., Simmons, B. J., Knapp, R. R., Elias, C. J., Campagna, J. J., Melnik, M., Chandra, S., Focht, S., Zhu, C., Vadivel, K., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00311 · Cited by 34
Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060
Mudražija, S., Aranda, M., Gaskin, D. J., Monroe, S., & Richard, P. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.13931 · Cited by 39
Circadian control of heparan sulfate levels times phagocytosis of amyloid beta aggregates
Clark, G. T., Yu, Y., Urban, C. A., Fu, G., Wang, C., Zhang, F., Linhardt, R. J., & Hurley, J. M. (2022) · PLOS Genetics · doi:10.1371/journal.pgen.1009994 · Cited by 31
Khan, M. M., Paez, H. G., Pitzer, C. R., & Alway, S. E. (2022) · Current Neuropharmacology · doi:10.2174/1570159x05666220908100545 · Cited by 32
Monfared, A. A. T., Khachatryan, A., Hummel, N., Kopiec, A., Martinez, M., Zhang, R. J., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231259 · Cited by 34
“Intangible costs of AD in the US have not been assessed as these costs are difficult to quantify [17, 18].”
BackgroundMolecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34
Dementia risk predictions from German claims data using methods of machine learning
Reinke, C., Doblhammer, G., Schmid, M. C., & Welchowski, T. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12663 · Cited by 37
A Literature Review on the Burden of Alzheimer’s Disease on Care Partners
Frederiksen, K., Lanctôt, K., Weidner, W., Hahn-Pedersen, J., & Mattke, S. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230487 · Cited by 22
“Theimpacts on care partners are not always captured in conventional economic evaluations, meaning the economic burden experienced by care partners is not always considered when assessing the value of a treatment or intervention [8, 9].”
Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease
Gustavsson, A., Pemberton-Ross, P., Montero, M. G., Hashim, M., & Thompson, R. (2020) · Expert review of pharmacoeconomics & outcomes research · doi:10.1080/14737167.2020.1822738 · Cited by 20
Jessen, F., Georges, J., Wortmann, M., & Benham‐Hermetz, S. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.22 · Cited by 33
“By 2030, it is estimated that the global cost of dementia could grow to US$2 trillion, which could impede socioeconomic development globally and overwhelm our health and social care systems (2, 3).”
BackgroundMethodInfluentialCerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers
Mirzaie, A., Nasrollahpour, H., Khalilzadeh, B., Jamali, A. A., Spiteri, R. J., Yousefi, H., Işıldak, İ., & Rahbarghazi, R. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117174 · Cited by 31
ALNasser, M. N., Mellor, I. R., & Carter, W. G. (2022) · Molecules · doi:10.3390/molecules27154891 · Cited by 31
“These diseases are of global concern as their prevalence is continuously increasing and is associated with an enormous socioeconomic burden [3].”
BackgroundWahlberg, K. E., Winblad, B. G., Cole, A., Herring, W. L., Ramsberg, J., Torontali, I., Visser, P. J., Wimo, A. B., Wollaert, L., & Jönsson, L. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13759 · Cited by 28
“Such ‘hidden’ costs are likely contributing to a significant proportion of the full real-life costs of AD and may also represent the most highly valued outcomes for patients and caregivers [29].”
BackgroundGuzzon, A., Rebba, V. S., Paccagnella, O., Rigon, M., & Boniolo, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285305 · Cited by 29
Global Societal Burden of Alzheimer’s Disease by Severity: a Targeted Literature Review
Cavaco, M., Jang, S., Olsen, C., Bodnar, C., & Ferko, N. (2025) · Neurological Therapeutics · doi:10.1007/s40120-025-00815-w · Cited by 25
“Variability in results can be partially attributed to different methods for calculating the monetary value, with the most common approach used being the opportunity costing method [32, 45, 67, 76, 78, 79].”
Modeling Neuroregeneration and Neurorepair in an Aging Context: The Power of a Teleost Model
houcke, J. V., Mariën, V., Zandecki, C., Seuntjens, E., Ayana, R., & Arckens, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.619197 · Cited by 25
Rao, R. V., Kumar, S., Gregory, J., Coward, C., Okada, S., Lipa, W., Kelly, L., & Bredesen, D. E. (2021) · Biomedicines · doi:10.3390/biomedicines9101348 · Cited by 29
Darmanthé, N., Initiative, A. D. N., Tabatabaei‐Jafari, H., & Cherbuin, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210092 · Cited by 23
“Individuals affected have typically lived with MCI for several years before progressing to AD dementia [7].”
Lynch, H. F., Caplan, A. L., Furlong, P., & Bateman-House, A. (2021) · The American Journal of Bioethics · doi:10.1080/15265161.2021.1974975 · Cited by 23
Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players
Pfrieger, F. W. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.766587 · Cited by 23
Fitzgerald, G. S., Chuchta, T. G., & McNay, E. C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14160 · Cited by 22
Interdisciplinary Research in Alzheimer’s Disease and the Roles International Societies Can Play
Tan, S., Zhao, R., Chakrabarti, S., Stambler, I., Jin, K., & Lim, L. (2021) · Aging and Disease · doi:10.14336/ad.2020.0602 · Cited by 15
“Consequently, this results in high costs to patients and healthcare systems [32, 33], making it one of the most expensive diseases even when compared to heart disease or cancer (https://act.”
BackgroundIntercepting Dementia: Awareness and Innovation as Key Tools
Brai, E., Tonacci, A., Brugada-Ramentol, V., D’Andrea, F., & Alberi, L. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.730727 · Cited by 25
“scot/ involve and connect different bodies, including policymakers, academia, private and public research sectors, hospitals, caregivers associations, and advocacy groups (El-Hayek et al., 2019; Steiner et al., 2020; Siva, 2021).”
BackgroundYawson, G. K., Will, M. F., Huffman, S. E., Strandquist, E. T., Bothwell, P. J., Oliver, E. B., Apuzzo, C. F., Platt, D. C., Weitzel, C. S., Jones, M. A., et al. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c01651 · Cited by 24
Alzheimer’s Disease Assessments Optimized for Diagnostic Accuracy and Administration Time
McCombe, N., Ding, X., Prasad, G., Gillespie, P., Finn, D. P., Todd, S., McClean, P. L., Wong‐Lin, K., & Initiative, A. D. N. (2022) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2022.3164806 · Cited by 23
“Dementia, of which Alzheimer’s disease (AD) is the most common type, causes enormous global socioeconomic burden [1].”
Das, M., Mao, W., Shao, E., Tamhankar, S., Yu, G.-Q., Yu, X., Ho, K., Wang, X., Wang, J., & Mucke, L. (2021) · iScience · doi:10.1016/j.isci.2021.103245 · Cited by 21
Bellantuono, L., Monaco, A., Amoroso, N., Lacalamita, A., Pantaleo, E., Tangaro, S., & Bellotti, R. (2022) · Frontiers in Big Data · doi:10.3389/fdata.2022.1027783 · Cited by 22
“1% of global GDP, including direct medical costs, social care costs, and caregiver income losses (WHO, 2015; El-Hayek et al., 2019).”
BackgroundBraun, A. L., Höfler, M., & Auer, S. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.12 · Cited by 20
“…al. (2019) who showed that an early detection of dementia has evident impact on clinical and social support but from an economic perspective, the early detection strategy dismantle hidden costs but have just minor impact on health care costs in general because it does not prevent them (16, 33, 34).”
Coluzzi, D., Bordin, V., Rivolta, M. W., Fortel, I., Zhan, L., Leow, A., & Baselli, G. (2025) · Bioengineering · doi:10.3390/bioengineering12010082 · Cited by 28
“As the population continues to age, dementia cases are on the rise, imposing serious public health risks and a huge social and economic burden on several countries [1].”
Deo, P., Dhillon, V. S., Chua, A., Thomas, P., & Fenech, M. F. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz259 · Cited by 19
“Alzheimer’s disease (AD), the most common form for dementia, has recently become a worldwide health concern, with a current estimate of 44 million people living with dementia and the number predicted to reach 135 million by 2050 (1).”
BackgroundQT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
Malone, K., & Hancox, J. C. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620942416 · Cited by 26
Doblhammer, G., Fritze, T., Reinke, C., & Fink, A. (2022) · Journal of Population Ageing · doi:10.1007/s12062-022-09365-7 · Cited by 18
“Will dementia ever be the most prevalent disease at the time of death in the elderly? Dementia is one of the most expensive diseases (El-Hayek et al. 2019), and the care of people with dementia involves a considerable (in)formal care burden.”
BackgroundThe Social Cost of Providing Care to Older Adults With and Without Dementia
Patterson, S., Tate, A. M., Hu, Y., Wang, J., Schoeni, R. F., & Choi, H. (2022) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbac146 · Cited by 21
New insights into the therapeutic approaches for the treatment of tauopathies
Singh, H., Das, A., Khan, M. M., & Pourmotabbed, T. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385288 · Cited by 20
Lei, M., Guo, X., Yao, Y., Shu, T., Ren, Z., Yang, X., Ouyang, C., Chen, Q., Liu, C., & Liu, X. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112307 · Cited by 20
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia
Skillbäck, T. B., Jönsson, L., Skoog, I. G., Blennow, K., Eriksdotter, M., Zetterberg, H., & Kern, S. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0693 · Cited by 22
Power, M. C., Engelman, B., Wei, J., & Glymour, M. M. (2022) · Epidemiologic Reviews · doi:10.1093/epirev/mxac002 · Cited by 18
Zdanovskis, N., Platkājis, A., Kostiks, A., Šneidere, K., Stepens, A., Naglis, R., & Karelis, G. (2022) · Medicina · doi:10.3390/medicina58070887 · Cited by 19
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls
Bhatti, J. S., Khullar, N., Mishra, J., Kaur, S., Sehrawat, A., Sharma, E., Bhatti, G. K., Selman, A., & Reddy, P. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166712 · Cited by 22
Tonelli, M. A., Wiebe, N., Joanette, Y., Hemmelgarn, B. R., So, H., Straus, S. E., James, M. T., Manns, B., & Klarenbach, S. W. (2022) · CMAJ Open · doi:10.9778/cmajo.20210035 · Cited by 17
Postu, P., Mihășan, M., Gorgan, D., Sadiki, F. Z., Idrissi, M. E., & Hrițcu, L. (2022) · Biomedicines · doi:10.3390/biomedicines10092300 · Cited by 17
“Although the social and psychological burden remains difficult to quantify [4], the financial burden associated with AD is staggering, reaching $818 billion in 2015 [5] and being expected to increase to more than $2 trillion by 2030 [6].”
BackgroundVasileva, L. A., Gaynanova, G. A., Romanova, E. A., Petrov, K. A., Feng, C., Zakharova, L. Y., & Sinyashin, O. G. (2024) · Russian Chemical Reviews · doi:10.59761/rcr5150 · Cited by 15
Wagner, A., Zúñiga, F., Rüesch, P., Schaffert, R., & Dratva, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244577 · Cited by 20
Thompson, L. I., Gaster, B., Hammers, D. B., Fittipaldi, S., Barrett, A. M., Partrick, K. A., Scholler, E., Tiede, B., Butler, C., & Workgroup, T. C. D. C. A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70966 · Cited by 17
Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis
Walker, A. C., Bhargava, R., Dove, A. S., Brust, A. S., Owji, A. A., & Czyż, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094807 · Cited by 18
“PCDs such as Alzheimer’s, Parkinson’s, Huntington’s, or amyotrophic lateral sclerosis (ALS) cause a massive loss of life and impose enormous social and financial burdens on afflicted individuals and their families [2].”
BackgroundSeibyl, J. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264773 · Cited by 18
“Costs associated with AD include nursing home care, physician visits, hospitalizations, and treatment, as well as costs that are more dif fi cult to account for, such as loss of productivity and uncompensated hours of care provided by family members ( 4 ).”
BackgroundUsing digital assessment technology to detect neuropsychological problems in primary care settings
Libon, D. J., Matusz, E. F., Cosentino, S., Price, C. C., Swenson, R., Vermeulen, M. W., Ginsberg, T. B., Okoli-Umeweni, A. O., Powell, L. A., Nagele, R. G., et al. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1280593 · Cited by 18
U.S. dementia care spending by state: 2010–2019
Lastuka, A., Breshock, M. R., McHugh, T. A., Sogge, W. T., Swart, V. M., & Dieleman, J. L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13746 · Cited by 14
Kumar, V., Kumar, B., Dwivedi, A. R., Mehta, D., Kumar, N., Bajaj, B., Arora, T., Prashar, V., Parkash, J., & Kumar, V. (2020) · ChemistrySelect · doi:10.1002/slct.202002425 · Cited by 15
Rodrigues, G. D. S., Noronha, N. Y., Noma, I. H. Y., de Lima, J. G. R., Sobrinho, A. C. D. S., Pinhel, M. A. D. S., de Almeida, M. L., Watanabe, L. M., Nonino, C. B., & Júnior, C. R. B. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112362 · Cited by 14
Sanchís, I., Spinelli, R., Aschemacher, N. A., & Siano, Á. (2021) · Amino Acids · doi:10.1007/s00726-021-03096-3 · Cited by 13
Rasheed, A., Zaheer, A. B., Munawwar, A., Sarfraz, Z., Sarfraz, A., Robles‐Velasco, K., & Chérrez-Ojeda, I. (2022) · Life · doi:10.3390/life13010001 · Cited by 15
Gulbranson, D. R., Ho, K., Yu, G.-Q., Yu, X., Das, M. M., Shao, E., Kim, D., Zhang, W. J., Choudhary, K., Thomas, R., et al. (2021) · eNeuro · doi:10.1523/eneuro.0089-21.2021 · Cited by 15
Xiang, W., Shen, Y., Chen, S., Tan, H., Cao, Q., & Xu, L. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.06.007 · Cited by 15
Caregivers’ Sense of Coherence: Implications on Direct and Indirect Costs of Dementia Care
Turró-Garriga, O., Viñas-Díez, V., Conde-Sala, J., Calvó-Perxas, L., Cullell-Juncà, M., Mas-Vall-Llosera, G., Flaqué, M., Turón-Estrada, A., Juvinyà-Canal, D., Mioshi, E., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200350 · Cited by 9
Li, B., Xie, P., Hao, Y., Guo, Y. L., Yu, J.-R., Gong, D., Guo, J., Zeng, J., & Zhang, Y. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11918 · Cited by 13
“Due to the high socioeconomic costs associated with patients with AD worldwide (6,7), the development of effective therapies to treat AD is of great significance.”
BackgroundMartins, R., Kotsopoulos, N., Michalowsky, B., Pemberton-Ross, P. J., Urbich, M., & Connolly, M. P. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.53 · Cited by 11
“Caregivers are also likely to increase outof-pocket expenses, reducing their ability to save for their retirement (13).”
Background
Metadata
- Authors
- El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A.
- Affiliations
- Shift Health, Toronto, ON, Canada
- McMaster University (CA)
- University of Exeter (GB)
- Alzheimer’s Research UK (GB)
- Barcelonaβeta Brain Research Center, Barcelona, Spain
- Brigham and Women's Hospital (US)
- Corresponding author
- Atri, Alireza
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2019-07-23
- Volume
- 70
- Issue
- 2
- Pages
- 323-341
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6700654
- OpenAlex
- W2954682095
- Cited by
- 216
- References
- 132
- Citations by year
- 2026: 10 · 2025: 33 · 2024: 28 · 2023: 34 · 2022: 47 · 2021: 40 · 2020: 23 · 2019: 1
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
- Funders
- F. Hoffmann-La Roche
- National Institute on Aging (P30AG019610)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, related dementias
- MeSH terms
- Stakeholder Participation, Alzheimer Disease, Dementia, Humans, Socioeconomic Factors, Global Health, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.